Sarepta Therapeutics (SRPT) PT Raised to $200 at Baird, 'Best Case Label'
Tweet Send to a Friend
(Updated - June 21, 2024 5:41 AM EDT)
Baird analyst Brian Skorney raised the price target on Sarepta Therapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Baird analyst Brian Skorney raised the price target on Sarepta Therapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
